Does metformin alone or in combination reduce morbidity and mortality in subjects with heart failure and type 2 diabetes compared with sulfonylurea monotherapy?
Metformin use is associated with improved clinical outcomes (lower morbidity and mortality) in patients with concurrent heart failure and type 2 diabetes compared to sulfonylurea monotherapy.
Metformin, alone or in combination, in subjects with heart failure and type 2 diabetes was associated with lower morbidity and mortality compared with sulfonylurea monotherapy.
Eurich et al. (Sat,) studied this question.